NCT00628095

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7 RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELY CONTROLLED ON METHOTREXATE

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis

Conditions

• Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	CE-224,535	500 mg po BID
DRUG	Placebo	no active ingredient

Timeline

• Start date: 2008-04-07
• Primary completion: 2009-02-04
• Completion: 2009-02-04
• First posted: 2008-03-04
• Last updated: 2022-04-04
• Results posted: 2022-04-04

Locations

27 sites across 7 countries: United States, Chile, Czechia, Mexico, Poland, South Korea, Spain